Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company dedicated to developing innovative treatments for age-related neurological disorders. The company’s main product candidate is neflamapimod, an orally administered small molecule that penetrates the brain to inhibit p38MAP kinase alpha (p38α). This investigational drug is being developed to address synaptic dysfunction, a reversible aspect of neurodegenerative diseases such as dementia with Lewy bodies (DLB).
Recent achievements for CervoMed include the completion of patient enrollment in the RewinD-LB Phase 2b study, which is a critical step in evaluating neflamapimod's efficacy in treating DLB. This milestone reflects the company’s operational capability and the high engagement levels across clinical sites. CervoMed's financial health is robust, supported by a $21 million grant from the National Institutes of Health's National Institute on Aging (NIA) and a $50 million financing deal, which is expected to provide a financial runway through the end of 2025.
In terms of research and development, the company has shown significant progress. Neflamapimod has demonstrated the potential to modulate cholinergic dysfunction and degeneration in preclinical and clinical studies, thereby improving cognitive and motor tasks. The ongoing RewinD-LB trial aims to provide a clear path to market for neflamapimod by the end of 2024.
CervoMed also boasts a series of strategic updates, including the successful listing on NASDAQ and strengthening its leadership team. The company's leadership includes industry veterans like Joshua Boger, Ph.D., who serves as non-executive Chair of the Board, and John Alam, MD, the Chief Executive Officer. The company continues to publish data that reinforces neflamapimod's potential as a highly differentiated, first-to-market treatment option for patients with DLB.
CervoMed’s commitment to advancing neurological health is evident through its collaborations with academic researchers and participation in prominent scientific forums. Notably, the company’s ongoing efforts include exploring additional therapeutic applications for neflamapimod in other cholinergic dysfunction-driven neurological disorders.
With its strong financial foundation and promising clinical pipeline, CervoMed Inc. is well-positioned to make significant strides in the treatment of age-related neurological disorders, ultimately aiming to improve the quality of life for patients globally.
CervoMed (NASDAQ: CRVO) announced it will present detailed safety and efficacy results from its RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the International Lewy Body Dementia Conference in January 2025. The company expects to release topline data from the study in December 2024. The presentation will take place during the Therapeutics in DLB session on January 31, 2025.
CEO John Alam expressed confidence in the trial design's ability to detect statistically significant and clinically meaningful differences between neflamapimod and placebo, noting there are currently no approved therapies for DLB.
CervoMed Inc. (NASDAQ: CRVO) has announced the Last Patient Last Visit in its Phase 2b RewinD-LB clinical trial evaluating neflamapimod for early-stage dementia with Lewy bodies (DLB). The company is on track to report topline efficacy and safety data in December 2024. Key highlights include:
- 96% of enrolled patients completed the 16-week double-blind placebo-controlled portion
- 98% of those patients continued into the open label extension
- The Data Safety Monitoring Board concluded the study may proceed without modification
- CervoMed will present late-breaking oral presentations at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference
The company believes neflamapimod has the potential to restore function and improve cognitive and motor functions in DLB patients, addressing a significant unmet need in this population.
CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for age-related neurologic disorders, announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference in New York on October 9, 2024. Dr. John Alam, CEO of CervoMed, will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications' at 8:00am ET.
The conference provides CervoMed with a platform to engage with investors through one-on-one meetings, potentially increasing visibility for the company's innovative approach to addressing age-related neurologic disorders. This event offers an opportunity for CervoMed to showcase its progress and strategy in pursuing significant market opportunities within the healthcare sector.
CervoMed Inc. (NASDAQ: CRVO) announced two late-breaking oral presentations at the upcoming Clinical Trials on Alzheimer's Disease Conference (CTAD) in Madrid, Spain. The presentations will focus on the potential of neflamapimod as a treatment for dementia with Lewy bodies (DLB). The first presentation will discuss plasma biomarker data from the AscenD-LB Phase 2a study, indicating neflamapimod's effect on the underlying disease process in DLB. The second presentation will cover baseline data from the RewinD-LB Phase 2b study, demonstrating the disease burden at study entry. CervoMed's CEO, John Alam, expressed confidence in a positive outcome for the RewinD-LB trial, with topline data expected in December 2024.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: A fireside chat on Friday, September 6, 2024, at 1:50 PM ET.
2. H.C. Wainwright 26th Annual Global Investment Conference: A corporate presentation on Wednesday, September 11, 2024, at 8:30 AM ET.
Webcasts of both presentations will be available on the CervoMed website's Investor section. These conferences provide an opportunity for CervoMed to showcase its progress and engage with potential investors.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, was featured in Fortune magazine for its work on neflamapimod, a potential treatment for dementia with Lewy bodies (DLB). The article, "A New Hope for Dementia Treatment," highlights CervoMed's Phase 2a AscenD-LB trial results, which suggest neflamapimod may slow cognitive and motor decline and partially restore functions in DLB patients.
CEO John Alam emphasized the critical need for DLB treatments, noting it affects over 1.4 million people in the U.S. The company anticipates sharing topline results from its Phase 2b RewinD-LB study in December 2024. Additionally, Dr. Alam recently discussed CervoMed's advancements on the Biotech 2050 podcast.
CervoMed Inc. (NASDAQ: CRVO) reported its Q2 2024 financial results and provided corporate updates. Key highlights include:
1. Completed enrollment in the RewinD-LB Phase 2b trial for neflamapimod in early-stage dementia with Lewy bodies (DLB), with topline data expected in December 2024.
2. Raised up to $149.4 million in a private placement, extending cash runway through 2025.
3. Added to Russell 2000® and Russell 3000® Indexes.
4. Q2 2024 financials: $50.9 million cash on hand, $5.6 million grant revenue for H1 2024, R&D expenses of $3.8 million, G&A expenses of $2.5 million, and a net loss of $2.3 million.
The company remains focused on developing treatments for age-related neurologic disorders, with neflamapimod showing potential in DLB and other neurological conditions.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company developing treatments for age-related neurologic disorders, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston, MA. The company's management will engage in a fireside chat on Tuesday, August 13, 2024, at 12:30 PM ET.
Investors can access the webcast of the fireside chat through a provided link or via the Investors section of CervoMed's website. Additionally, the company will be available for one-on-one investor meetings during the conference, offering an opportunity for more in-depth discussions about CervoMed's progress and future plans in the field of neurologic disorder treatments.
CervoMed Inc. (NASDAQ: CRVO) presented plasma biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB) at the Alzheimer's Association International Conference® 2024. Key findings include:
1. Baseline plasma glial fibrillary acidic protein (GFAP) levels correlated with dementia severity in DLB patients.
2. Neflamapimod treatment significantly reduced plasma GFAP levels in early-stage DLB patients without Alzheimer's disease co-pathology.
3. In early-stage DLB patients, GFAP reduction was associated with improved clinical outcomes.
These results suggest neflamapimod's potential to address the underlying disease process in early-stage DLB. CervoMed's ongoing RewinD-LB Phase 2b trial is optimized based on these findings, with topline data expected in December 2024.
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company specializing in treatments for age-related neurologic disorders, has announced its participation in the upcoming Emerging Growth Conference. The company's management will deliver a virtual corporate presentation on Thursday, July 18, 2024, at 1:10 PM ET.
Investors and interested parties can access the webcast of the presentation through the provided link or via the Investor section of CervoMed's official website. This event offers an opportunity for stakeholders to gain insights into CervoMed's current projects, future plans, and potential growth prospects in the field of neurologic disorder treatments.
FAQ
What is the current stock price of CervoMed (CRVO)?
What is the market cap of CervoMed (CRVO)?
What is CervoMed Inc. focused on?
What is neflamapimod?
What is the RewinD-LB Phase 2b study?
What recent milestones has CervoMed achieved?
How is CervoMed funded?
Is neflamapimod safe?
What is the potential market impact of neflamapimod?
Who are the key leaders at CervoMed?
What are the next steps for CervoMed?
Where can I find more information about CervoMed’s clinical trials?
